Maxime Dougados
0000-0003-3009-6229
37 papers found
Refreshing results…
Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative
Disease activity and widespread pain are main contributors to patient-reported global health in axial spondyloarthritis: an analysis of 6064 patients
Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort
Factors Associated With Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-Year Follow-Up of the DESIR Cohort
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study
Sex differential impact of comorbidities in spondyloarthritis: data from COMOSPA study
Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature
Ten-Year Clinical Outcome of recent-onset Axial Spondyloarthritis: results from the DESIR inception Cohort
Impact of disease outcomes on the Assessment of SpondyloArthritis International Society Health Index (ASAS HI): a Bayesian network analysis of the DESIR cohort
Determinants of health-related quality of life and global functioning and health in axSpA, pSpA, and PsA: results from the ASAS-PerSpA study
Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)
Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Missing publications? Search for publications with a matching author name.